What This Trial Looked At
Lymphedema after breast cancer treatment — chronic swelling of the arm caused by damage to lymph nodes during surgery and radiotherapy — is one of the most enduring quality-of-life burdens for breast cancer survivors. Standard care relies on compression garments, manual lymphatic drainage, and skin care, which require significant daily commitment from patients and offer only partial relief for many. In 2003 an Australian research team led by Carolyn Carati at the University of South Australia published a randomised, double-blind, placebo-controlled trial in the journal Cancer testing whether low-level laser therapy could meaningfully reduce arm volume and improve tissue quality in this population.
The trial enrolled 64 women with chronic, unilateral post-mastectomy lymphedema of at least three months’ duration. Participants were randomised to receive one or two cycles of low-level laser therapy (904 nm) applied to the axillary region of the affected arm, or sham treatment with an identical-looking inactive device. Outcomes were measured at multiple time points up to three months after the final treatment cycle and included limb volume (perometry), tissue induration (tonometry), and pain.
What They Found
Two cycles of LLLT produced significant reductions in affected limb volume compared with sham at the three-month follow-up. The effect was not immediate — it became apparent over time as the treatment cycles took effect and lymphatic drainage gradually improved.
Tissue induration — the hardening of the arm that accompanies chronic lymphedema — also improved significantly in the laser-treated group. Pain scores decreased. Across the panel of outcomes the laser group showed consistent improvement; the sham group showed essentially no change.
What This Means in Context
This trial is one of the foundational pieces of evidence supporting low-level laser therapy as a recognised treatment option for post-mastectomy lymphedema. Publication in Cancer — a leading oncology journal — and the methodological rigour of the design (randomised, double-blind, sham-controlled, with objective volumetric measurement) gave the result substantial weight.
LLLT for lymphedema has since been incorporated into several professional society recommendations as a Grade B evidence option for chronic post-mastectomy arm lymphedema. The trial does not by itself establish the optimal protocol for every patient — the dose parameters, number of cycles, and combination with manual lymphatic drainage are still being refined in subsequent studies — but it establishes the principle that photobiomodulation can meaningfully shift a condition that previous decades had treated only through mechanical interventions.
What It Means for You
If you or someone you love is managing post-mastectomy lymphedema, this trial is part of the well-established evidence supporting low-level laser therapy as a supportive option that may reduce limb volume, soften the affected tissue, and ease pain. Photobiomodulation works alongside — not instead of — the compression and lymphatic drainage routine your oncology rehabilitation team has prescribed. Any complementary approach in the setting of cancer survivorship should be discussed with your treating oncology or lymphedema-care specialist first.
Citation: Carati, C.J., Anderson, S.N., Gannon, B.J., & Piller, N.B. (2003). Treatment of postmastectomy lymphedema with low-level laser therapy: a double blind, placebo-controlled trial. Cancer, 98(6), 1114-1122. PubMed
